Findings from a systematic review of several observational studies reveal that increasing disparities in survival outcomes within hematologic malignancies can be primarily attributed to 5 social determinants of health: lack of access to health insurance, treatment at a non-academic facility, low income or education level, and unmarried status.
Varying outcomes among adolescent and young adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia treated with pediatric-inspired protocols or adult chemotherapy regimens warrant further study.
Current research suggests that circulating tumor DNA may have prognostic value when conducted at the conclusion of treatment in large B-cell lymphoma, indicating that minimal residual disease detection using ctDNA assessments such as PhaseEd-Seq could address imitations associated with the use of computed tomography or positron emission tomography/CT scans at this stage.
Varying outcomes were observed among adolescent and young adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia who were treated with pediatric-inspired protocols vs adult chemotherapy regimens.
/PRNewswire/ Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today.